{"id":53561,"date":"2023-02-02T11:02:40","date_gmt":"2023-02-02T10:02:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/"},"modified":"2023-02-02T11:02:40","modified_gmt":"2023-02-02T10:02:40","slug":"agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/","title":{"rendered":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease"},"content":{"rendered":"
\n

\n— All dosing regimens were well-tolerated across the Phase 1 clinical study —\n<\/p>\n

\n— High local exposure to AGMB-129 in the ileum —\n<\/p>\n

\n— No clinically relevant systemic exposure to AGMB-129, confirming GI-tract targeted exposure —\n<\/p>\n

GHENT, Belgium–(BUSINESS WIRE)–Agomab Therapeutics NV<\/a> (\u2018Agomab\u2019) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGF\u03b2<\/span>RI or ALK5), intended for the treatment of Fibrostenosing Crohn\u2019s Disease (FSCD). The trial, designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AGMB-129 in healthy subjects, demonstrated high local exposure to AGMB-129 in the ileum and no clinically relevant systemic exposure.\n<\/p>\n

<\/a><\/p>\n

\nThe Phase 1 study included single ascending dose (SAD), multiple ascending dose (MAD) and food-effect (FE) stages, as well as an additional stage for the assessment of local drug exposure in ileal mucosa, where the fibrostenotic strictures in FSCD patients are most often located. A total of 81 healthy subjects were randomized to receive either single or multiple daily oral doses of AGMB-129, or matching placebo.\n<\/p>\n

\nAGMB-129 was well-tolerated at all doses tested. The incidence and intensity of adverse events were similar across all dose cohorts including the placebo cohort. No drug-related safety signal or dose-limiting toxicities were identified. The favorable safety profile from the Phase 1 study supports the evaluation of AGMB-129 in a planned global Phase 2a study in patients with FSCD. Plasma PK analyses showed no clinically relevant systemic exposure, whereas biopsies of the ileum showed high local concentrations of AGMB-129, confirming that the GI-restriction mechanism can operate efficiently in humans.\n<\/p>\n

\n\u201cThe positive results of this Phase 1 study are an important first step in our clinical development of AGMB-129 and confirm its tolerability and GI-restricted mechanism,\u201d said Philippe Wiesel, Chief Medical Officer at Agomab Therapeutics<\/b>. \u201cWe look forward to advancing AGMB-129 into a global Phase 2a study in patients with Fibrostenosing Crohn\u2019s Disease, a disease for which there are currently no medicinal products available.\u201d\n<\/p>\n

\nAbout AGMB-129
\n
<\/b>AGMB-129 is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGF\u03b2<\/span>R1) for the treatment of Fibrostenosing Crohn\u2019s Disease (FSCD). TGF\u03b2<\/span> is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in fibrotic indications. AGMB-129 is specifically designed to inhibit ALK5 in the GI-tract. Rapid first-pass metabolism in the liver prevents clinically relevant systemic exposure, delivering an improved safety profile over other inhibitors in its class. Fibrostenotic complications occur in up to 50% of Crohn\u2019s disease patients and are the leading cause of bowel resection surgery. Yet, there are no approved specific therapies for FSCD.\n<\/p>\n

\nAbout Agomab
\n
<\/b>Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Agomab Therapeutics
\n
Tim Knotnerus, CEO
\n
E-Mail: tim.knotnerus@agomab.com<\/a>\n<\/p>\n

\nMedia Requests for Agomab<\/b>
Dr. Stephanie May or Eva Mulder
\n
Trophic Communications
\n
Phone: + 49 171 185 5682
\n
E-Mail: agomab@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

— All dosing regimens were well-tolerated across the Phase 1 clinical study — — High local exposure to AGMB-129 in the ileum — — No clinically relevant systemic exposure to AGMB-129, confirming GI-tract targeted exposure — GHENT, Belgium–(BUSINESS WIRE)–Agomab Therapeutics NV (\u2018Agomab\u2019) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53561","6":"format-standard","7":"category-industry"},"yoast_head":"\nAgomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"— All dosing regimens were well-tolerated across the Phase 1 clinical study — — High local exposure to AGMB-129 in the ileum — — No clinically relevant systemic exposure to AGMB-129, confirming GI-tract targeted exposure — GHENT, Belgium–(BUSINESS WIRE)–Agomab Therapeutics NV (\u2018Agomab\u2019) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-02T10:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230202005442\/en\/1703802\/21\/New_AgomabLogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease\",\"datePublished\":\"2023-02-02T10:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230202005442\\\/en\\\/1703802\\\/21\\\/New_AgomabLogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/\",\"name\":\"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230202005442\\\/en\\\/1703802\\\/21\\\/New_AgomabLogo.jpg\",\"datePublished\":\"2023-02-02T10:02:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230202005442\\\/en\\\/1703802\\\/21\\\/New_AgomabLogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230202005442\\\/en\\\/1703802\\\/21\\\/New_AgomabLogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/","og_locale":"en_US","og_type":"article","og_title":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease - Pharma Trend","og_description":"— All dosing regimens were well-tolerated across the Phase 1 clinical study — — High local exposure to AGMB-129 in the ileum — — No clinically relevant systemic exposure to AGMB-129, confirming GI-tract targeted exposure — GHENT, Belgium–(BUSINESS WIRE)–Agomab Therapeutics NV (\u2018Agomab\u2019) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-02T10:02:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230202005442\/en\/1703802\/21\/New_AgomabLogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease","datePublished":"2023-02-02T10:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/"},"wordCount":534,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230202005442\/en\/1703802\/21\/New_AgomabLogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/","url":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/","name":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230202005442\/en\/1703802\/21\/New_AgomabLogo.jpg","datePublished":"2023-02-02T10:02:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230202005442\/en\/1703802\/21\/New_AgomabLogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230202005442\/en\/1703802\/21\/New_AgomabLogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/agomab-reports-positive-phase-1-results-with-agmb-129-a-gi-restricted-alk5-inhibitor-for-fibrostenosing-crohns-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53561"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53561\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}